NASDAQ:LPCN

Lipocine Stock News

Healthcare > Biotechnology

Buy LPCN

*Your capital is at risk

$2.12

+0.0100 (+0.474%)

At Close: Jul 31, 2026

Lipocine Receives FDA Clearance For Clinical Testing Of Its NASH Candidate, LPCN 1144, In Expanded Target Population

12:00am, Tuesday, 23'rd Jul 2019

18 Stocks Joining The Russell Indices

12:00am, Friday, 28'th Jun 2019

Lipocine Set To Join Russell Microcap Index , Effective Jul. 1

12:00am, Tuesday, 25'th Jun 2019

Lipocine Announces TLANDO NDA PDUFA Action Date Of November 9, 2019

12:00am, Tuesday, 14'th May 2019

Lipocine Q1 EPS $(0.14), Inline

12:00am, Wednesday, 08'th May 2019

48 Biggest Movers From Friday

12:00am, Monday, 15'th Apr 2019

Clarus Therapeutics Has Refuted Patent Infringement Complaint By Lipocine

12:00am, Wednesday, 03'rd Apr 2019

Lipocine Shares Tick Lower As Traders Circulate FDA Access Data Doc Showing Approval For Competitor Clarus Therapeutics' Jatenzo

12:00am, Wednesday, 27'th Mar 2019

Lipocine Reports Acceptance Of Abstract Of Late-Breaker Presentation On LPCN 1144 Results As Part Of EASL

12:00am, Tuesday, 26'th Mar 2019

Lipocine Reports Has Been Selected To Present LPCN 1144 Results at ENDO 2019

12:00am, Thursday, 14'th Mar 2019

48 Stocks Moving In Wednesday's Mid-Day Session

12:00am, Wednesday, 13'th Mar 2019

Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

12:00am, Tuesday, 12'th Mar 2019

Lipocine Q4 EPS $(0.55) Misses $(0.13) Estimate, Sales $428.031K

12:00am, Wednesday, 06'th Mar 2019

Lipocine Stock News

Lipocine Receives FDA Clearance For Clinical Testing Of Its NASH Candidate, LPCN 1144, In Expanded Target Population

18 Stocks Joining The Russell Indices

Lipocine Set To Join Russell Microcap Index , Effective Jul. 1

Lipocine Announces TLANDO NDA PDUFA Action Date Of November 9, 2019

Lipocine Q1 EPS $(0.14), Inline

48 Biggest Movers From Friday

Clarus Therapeutics Has Refuted Patent Infringement Complaint By Lipocine

Lipocine Shares Tick Lower As Traders Circulate FDA Access Data Doc Showing Approval For Competitor Clarus Therapeutics' Jatenzo

Lipocine Reports Acceptance Of Abstract Of Late-Breaker Presentation On LPCN 1144 Results As Part Of EASL

Lipocine Reports Has Been Selected To Present LPCN 1144 Results at ENDO 2019

48 Stocks Moving In Wednesday's Mid-Day Session

Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

Lipocine Q4 EPS $(0.55) Misses $(0.13) Estimate, Sales $428.031K

Lipocine Inc. Rpoerts FDA Clearance Of IND to Commence Phase 2 Study Of LPCN 1144 In Biopsy Confirmed NASH Subjects

Lipocine: A Micro-Cap Stock That Can Compete In The NASH/NAFLD Race

Top Fintech Company